Literature DB >> 32917788

Foot-and-Mouth Disease Virus 3B Protein Interacts with Pattern Recognition Receptor RIG-I to Block RIG-I-Mediated Immune Signaling and Inhibit Host Antiviral Response.

Xiangle Zhang1, Zixiang Zhu1, Congcong Wang1, Fan Yang1, Weijun Cao1, Pengfei Li1, Xiaoli Du1, Furong Zhao1,2, Xiangtao Liu1,3, Haixue Zheng4.   

Abstract

Foot-and-mouth disease is a highly contagious disease of pigs, sheep, goats, bovine, and various wild cloven-hoofed animals caused by foot-and-mouth disease virus (FMDV) that has given rise to significant economic loss to global livestock industry. FMDV 3B protein is an important determinant of virulence of the virus. Modifications in 3B protein of FMDV considerably decrease virus yield. In the current study, we demonstrated the significant role of 3B protein in suppression of type I IFN production and host antiviral response in both human embryonic kidney HEK293T cells and porcine kidney PK-15 cells. We found that 3B protein interacted with the viral RNA sensor RIG-I to block RIG-I-mediated immune signaling. 3B protein did not affect the expression of RIG-I but interacted with RIG-I to block the interaction between RIG-I and the E3 ubiquitin ligase TRIM25, which prevented the TRIM25-mediated, Lys63-linked ubiquitination and activation of RIG-I. This inhibition of RIG-I-mediated immune signaling by 3B protein decreased IFN-β, IFN-stimulated genes, and proinflammatory cytokines expression, which in turn promoted FMDV replication. All of the three nonidentical copies of 3B could inhibit type I IFN production, and the aa 17A in each copy of 3B was involved in suppression of IFN-related antiviral response during FMDV infection in porcine cells. Together, our results indicate the role of 3B in suppression of host innate immune response and reveal a novel antagonistic mechanism of FMDV that is mediated by 3B protein.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32917788      PMCID: PMC7533709          DOI: 10.4049/jimmunol.1901333

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Immune signaling by RIG-I-like receptors.

Authors:  Yueh-Ming Loo; Michael Gale
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

3.  Genome-linked proteins of viruses.

Authors:  E Wimmer
Journal:  Cell       Date:  1982-02       Impact factor: 41.582

Review 4.  Inverse interference: how viruses fight the interferon system.

Authors:  Friedemann Weber; Georg Kochs; Otto Haller
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

5.  A diverse range of gene products are effectors of the type I interferon antiviral response.

Authors:  John W Schoggins; Sam J Wilson; Maryline Panis; Mary Y Murphy; Christopher T Jones; Paul Bieniasz; Charles M Rice
Journal:  Nature       Date:  2011-04-10       Impact factor: 49.962

Review 6.  Pattern recognition receptors and the innate immune response to viral infection.

Authors:  Mikayla R Thompson; John J Kaminski; Evelyn A Kurt-Jones; Katherine A Fitzgerald
Journal:  Viruses       Date:  2011-06-23       Impact factor: 5.048

Review 7.  Innate Immunity and Immune Evasion by Enterovirus 71.

Authors:  Prabuddha S Pathinayake; Alan C-Y Hsu; Peter A B Wark
Journal:  Viruses       Date:  2015-12-14       Impact factor: 5.048

Review 8.  Multifunctional roles of leader protein of foot-and-mouth disease viruses in suppressing host antiviral responses.

Authors:  Yingqi Liu; Zixiang Zhu; Miaotao Zhang; Haixue Zheng
Journal:  Vet Res       Date:  2015-10-28       Impact factor: 3.683

Review 9.  Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response.

Authors:  Miguel Rodríguez Pulido; Margarita Sáiz
Journal:  Front Cell Infect Microbiol       Date:  2017-06-13       Impact factor: 5.293

10.  Foot-and-mouth disease virus non-structural protein 3A inhibits the interferon-β signaling pathway.

Authors:  Dan Li; Caoqi Lei; Zhisheng Xu; Fan Yang; Huanan Liu; Zixiang Zhu; Shu Li; Xiangtao Liu; Hongbing Shu; Haixue Zheng
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

View more
  6 in total

1.  Multiple Viral Protein Genome-Linked Proteins Compensate for Viral Translation in a Positive-Sense Single-Stranded RNA Virus Infection.

Authors:  Reid Warsaba; Nikolay Stoynov; Kyung-Mee Moon; Stephane Flibotte; Leonard Foster; Eric Jan
Journal:  J Virol       Date:  2022-08-22       Impact factor: 6.549

2.  Porcine Sapelovirus 3Cpro Inhibits the Production of Type I Interferon.

Authors:  Mengge Yin; Wei Wen; Haoyuan Wang; Qiongqiong Zhao; Hechao Zhu; Huanchun Chen; Xiangmin Li; Ping Qian
Journal:  Front Cell Infect Microbiol       Date:  2022-06-15       Impact factor: 6.073

3.  Foot-and-Mouth Disease Virus Evades Innate Immune Response by 3C-Targeting of MDA5.

Authors:  Hyejin Kim; Ah-Young Kim; Jieun Choi; Sun Young Park; Sang Hyun Park; Jae-Seok Kim; Sim-In Lee; Jong-Hyeon Park; Choi-Kyu Park; Young-Joon Ko
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

Review 4.  Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion.

Authors:  Xiu-Zhong Zhang; Fu-Huang Li; Xiao-Jia Wang
Journal:  Front Microbiol       Date:  2021-12-01       Impact factor: 5.640

5.  Hazara Orthonairovirus Nucleoprotein Antagonizes Type I Interferon Production by Inhibition of RIG-I Ubiquitination.

Authors:  Keisuke Ohta; Naoki Saka; Machiko Nishio
Journal:  Viruses       Date:  2022-09-04       Impact factor: 5.818

6.  Bovine Delta Papillomavirus E5 Oncoprotein Interacts With TRIM25 and Hampers Antiviral Innate Immune Response Mediated by RIG-I-Like Receptors.

Authors:  Francesca De Falco; Anna Cutarelli; Ivan Gentile; Pellegrino Cerino; Valeria Uleri; Adriana Florinela Catoi; Sante Roperto
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.